← Stack Research Tool

Pair page

N-Acetyl Selank with N-Acetyl Semax

Mechanism-tag overlap and published literature for N-Acetyl Selank and N-Acetyl Semax, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.

Mechanism overlap

Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.

N-ACETYL SELANK N-ACETYL SEMAX 1 UNIQUE TAGS 2 UNIQUE TAGS 0 SHARED
N-Acetyl Selank unique tuftsin-family-anxiolytic
Shared none
N-Acetyl Semax unique 4-7stabilized-acth-nootropic-analog

Co-administration notes from the literature

Verbatim summary text pulled from each compound's profile data. Researchers studying N-Acetyl Selank and N-Acetyl Semax have published these mechanism-level observations. Not a co-administration recommendation.

Evidence level: mechanistic only

The classic stabilized-Russian nootropic pairing — Semax (cognitive drive, BDNF, attention) + Selank (GABA A -allosteric calm, anxiolysis). Pharmacodynamically complementary, used in Russian outpatient practice as a paired course.

Quick facts

N-Acetyl Selank

RouteIntranasal
Half-life~several hours (CNS, enhanced)
FDA statusNot listed
WADANot specifically named
Full N-Acetyl Selank profile →

N-Acetyl Semax

RouteIntranasal
Half-lifeNot listed
FDA statusNot listed
WADANot specifically named
Full N-Acetyl Semax profile →

Literature table

Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.

Year Compound Source Finding
2008N-Acetyl SelankUchakina ON, Uchakin PN, Miasoedov NF, Andreeva LA. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-75. PMID: 18577925. PMID 18577925human study
2017N-Acetyl SelankMedvedev VE, Tereshchenko OV, Kost NV, Ter-Israelyan AY, Gushanskaya EV, Chobanu IK, Sokolov OY, Miasoedov NF. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol. 2017;2017:5091027. PMC5322660.preclinical, in vivo
2009N-Acetyl SelankSemenova TP, Kozlovskii II, Zakharova NM, Kozlovskaia MM. Comparison of the effects of selank and tuftsin on the metabolism of serotonin in the brain of rats pretreated with PCPA. Eksp Klin Farmakol. 2009;72(4):6-8. PMID: 19803388. PMID 19803388preclinical, in vivo
2008N-Acetyl SelankInozemtseva LS, Karpenko EA, Dolotov OV, Levitskaya NG, Kamensky AA, Andreeva LA, Grivennikov IA. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008;421:241-243. PMID: 18841774. PMID 18841774preclinical, in vivo
2002N-Acetyl SelankKozlovskii II, Danchev ND. The optimizing action of the synthetic peptide selank on an active avoidance reflex in rats. Zh Vyssh Nerv Deiat Im I P Pavlova. 2002;52(5):579-584. PMID: 12449037. PMID 12449037preclinical, in vivo
1998N-Acetyl SelankSeredenin SB, Kozlovskaia MM, Blednov IuA, Kozlovskii II, Semenova TP, Czabak-Garbacz R. The anxiolytic action of an analog of the endogenous peptide tuftsin on inbred mice with different phenotypes of the emotional stress reaction. Zh Vyssh Nerv Deiat Im I P Pavlova. 1998;48(1)… PMID 9612605preclinical, in vivo
2016N-Acetyl SelankVolkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016 Feb 18;7:31. PMID: 26924986. PMID 26924986research article
2014N-Acetyl SelankKolomin T, Morozova M, Volkova A, Shadrina M, Andreeva L, Slominsky P, Limborska S, Myasoedov N. The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action. Mol Immunol. 2014;58(1):50-55. PMID: 24275703. PMID 24275703research article
2010N-Acetyl SelankAndreeva LA, Nagaev IY, Mezentseva MV, Shapoval IM, Podchernyaeva RY, Shcherbenko VE, Potapova LA, Rusakova EV, Miasoedov NF. Antiviral properties of structural fragments of the peptide Selank. Dokl Biol Sci. 2010;431:86-88. PMID: 20506848. PMID 20506848research article
2009N-Acetyl SelankErshov FI, Uchakin PN, Uchakina ON, Mezentseva MV, Alekseeva LA, Miasoedov NF. Antiviral activity of immunomodulator Selank in experimental influenza infection. Vopr Virusol. 2009;54(5):19-24. PMID: 19882898. PMID 19882898research article
2008N-Acetyl SelankZozulia AA, Neznamov GG, Siuniakov TS, Kost NV, Gabaeva MV, Sokolov OIu, Serebriakova EV, Siranchieva OA, Andriushenko AV, Telesheva ES, Siuniakov SA, Smulevich AB, Miasoedov NF, Seredenin SB. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the t… PMID 18454096research article
2003N-Acetyl SelankKozlovskaya MM, Kozlovskii II, Val'dman EA, Seredenin SB. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neurosci Behav Physiol. 2003;33(9):853-860. PMID: 14969428. PMID 14969428research article
2011N-Acetyl SemaxStavchansky VV, Yuzhakov VV, Botsina AY, Skvortsova VI, Bondurko LN, Tsyganova MG, Limborska SA, Myasoedov NF, Dergunova LV. The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: a pilot study.… PMID 21409522human pilot
2018N-Acetyl SemaxGusev EI, Martynov MY, Kostenko EV, Petrova LV, Bobyreva SN. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3. Vyp. 2):61-68. PMID: 29798983. PMID 29798983human study
2014N-Acetyl SemaxMedvedeva EV, Dmitrieva VG, Povarova OV, Limborska SA, Skvortsova VI, Myasoedov NF, Dergunova LV. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15… PMID 25476978preclinical, in vivo
2006N-Acetyl SemaxDolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LY, Kamensky AA, Grivennikov IA, Myasoedov NF, Engele J. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression… PMID 16996037preclinical, in vivo
2001N-Acetyl SemaxShadrina MI, Dolotov OV, Grivennikov IA, Slominsky PA, Andreeva LA, Inozemtseva LS, Limborska SA, Myasoedov NF. Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neurosci Lett. 2001;308(2):115-118. PMID: 11457574. PMID 11457574preclinical, in vivo
2023N-Acetyl SemaxDergunova LV, Filippenkov IB, Limborska SA, Myasoedov NF. Neuroprotective Peptides and New Strategies for Ischemic Stroke Drug Discoveries. Genes (Basel). 2023;14(5):953. PMID: 37239312. PMID 37239312research article
2005N-Acetyl SemaxEremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, Rayevsky KS. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500. PMID: 16362767. PMID 16362767research article
2004N-Acetyl SemaxLevitskaya NG, Sebentsova EA, Andreeva LA, Alfeeva LY, Kamenskii AA, Myasoedov NF. Investigation of the spectrum of physiological activities of a heptapeptide analog of ACTH(4-10) — Semax. Neurosci Behav Physiol. 2004;34(4):399-405. PMID: 15341214. PMID 15341214research article
1997N-Acetyl SemaxGusev EI, Skvortsova VI, Miasoedov NF, Nezavibat'ko VN, Zhuravleva EIu, Vanichkin AV. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34. PMID: 11517472. PMID 11517472research article
1997N-Acetyl SemaxAshmarin IP, Nezavibat'ko VN, Myasoedov NF, Kamenskii AA, Grivennikov IA, Ponomareva-Stepnaia MA, Andreeva LA, Kaplan AIa, Koshelev VB, Riasina TV. A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study). Zh Vyssh Nerv Deiat Im I P Pavlova… PMID 9234274research article

Related pair pages

More research context

Frequently asked

Have N-Acetyl Selank and N-Acetyl Semax been studied together?

Researchers have published mechanistic-level co-administration discussion of N-Acetyl Selank and N-Acetyl Semax. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.

What mechanisms do N-Acetyl Selank and N-Acetyl Semax share?

N-Acetyl Selank and N-Acetyl Semax do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.

What is the FDA status of N-Acetyl Selank and N-Acetyl Semax?

N-Acetyl Selank: Not listed. N-Acetyl Semax: Not listed. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.

Where can I find the full research on N-Acetyl Selank and N-Acetyl Semax?

Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the N-Acetyl Selank profile and the N-Acetyl Semax profile. The Kalios Stack Research Tool hub lists every compound covered.

Last updated: April 2026